SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development

About this update from Surenano Science Ltd

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with GlucaPharm Inc. ("GlucaPharm"), to conduct legal, technical and financial due diligence on GlucaPharm and its license to the intellectual property as described below (the "Proposed Transaction"). If the Company elects to proceed following the conclusion of its due diligence, the parties shall negotiate and enter into a definitive binding agreement (the "Definitive Agreement"). The LOI contains both binding and non-binding terms, the former including mutual confidentiality and due diligence access rights, each party bears own expenses and mutual exclusivity of negotiations, and the non-binding terms relating to the substantive terms of the Proposed Transaction share exchange terms. GlucaPharm is a privately held BC Corporation and holds exclusive rights to develop Syracuse University's GEP-44 GLP-1 pharmaceutical patent protected compound discovery and technology. GEP-44 is a novel compound that addresses diabetes and weight loss, similar to current in-market GLP-1s such as Ozempic, but targeting no-needle administration method and superior tolerability, including reduced side effects most experienced by leading in-market drugs such as nausea and gastrointestinal issues. GEP-44 is a triple antagonist with strong preclinical results, patents filed, academic validation and market exploration underway, poised to transform the treatment of obesity and diabetes worldwide. Proposed Transaction OverviewThe Proposed Transaction is expected to be structured as a share exchange pursuant to which SureNano will acquire 100% of the issued and outstanding common shares in the capital of GlucaPharm through the issuance of an aggregate number of common shares to GlucaPharm shareholders, to be agreed upon subject to completion of Due Diligence, in the capital of SureNano (the "SureNano Shares") upon closing of the Proposed Transaction via a share exchange agreement. Following the closing, it is expected that GlucaPharm shareholders will collectively own under 20% of the issued and outstanding SureNano Shares. The LOI sets out certain terms and conditions pursuant to ...

View stock analysis, news, and events for Surenano Science Ltd